All In Biotech

Drug Trial Radar · NCT06406153

Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients

A Phase III, Single Arm, Cross-over, Multicenter Clinical Trial to Compare Efficacy and Safety of YW17(Laronidase; CinnaGen) Versus Laronidase (Aldurazyme®; Genzyme, BioMarin) in Patients With Mucopolysaccharidosis Type I (MPS I)"

Last checked: Nov 20, 2026Latest source record: Aug 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12

Actual

Start

Sep 10, 2022

Primary completion

Aug 12, 2023

Study completion Nov 18, 2023

Sponsor

Lead sponsor
CinnagenIndustry
Sponsor type
Industry
First posted
May 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 5 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase III study is to assess the efficacy and safety of YW17 produced by CinnaGen Company compared to Aldurazyme® in mucopolysaccharidosis type I (MPS I) patients. All patients receive Aldurazyme® for 12 weeks, followed by YW17 for another 12 weeks. The primary outcome is the assessment of the maintenance of the mean uGAG levels at the end of each medication administration. The secondary outcomes are the assessment of 6-minute walking test (6MWT), predicted forced vital capacity (FVC), enzyme activity assay, and adverse events (AEs).

Conditions

  • Mucopolysaccharidosis Type 1

Interventions

  • LaronidaseBiological

    Laronidase as Aldurazyme® (the first 12 weeks) or YW17 (the second 12 weeks) is administered.

  • AntihistamineDrug

    An antihistamine is administered one hour before the infusion.

  • AntipyreticDrug

    An antipyretic is administered one hour before the infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. mean uGAGTime frame: Baseline, weeks 8, 10, 12, 20, 22, and 24

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Development Unit of Akbar Hospital, Faculty of Medicine

    Mashhad, Iran

  • Growth and Development Research Center, Childrens Medical Center

    Tehran, Iran

  • Loghman Hospital

    Tehran, Iran

  • Mofid Childrens Hospital

    Tehran, Iran

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.